Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 23

Sort by

Sort Order Select

Journal Articles

Higher abatacept exposure after transplant decreases acute GVHD risk without increasing adverse events

Blood (2023) 142 (8): 700–710.

https://doi.org/10.1182/blood.2023020035

Published: 2023

Includes: Supplemental data

Journal Articles

Phase I Study to Improve Anti-Viral Immunity after Cord Blood Transplantation Using Cord-Blood-Derived Multi-Virus-Specific T-Cells

Shweta Bansil, Cecilia Motta, Rachel Dicioccio, Samuel O'Brien, Haili Lang, Michael Keller, Allistair Abraham, David Jacobsohn, Blachy J Davila Saldana, Amanda L. Olson, Elizabeth J Shpall, Indreshpal Kaur, Patrick J Hanley, Catherine M Bollard

Blood (2022) 140 (Supplement 1): 10239–10240.

https://doi.org/10.1182/blood-2022-167874

Published: 2022

Journal Articles

Outcome of Donor-Derived Tumor Associated Antigen-Specific T Cell Therapy in Patients with High-Risk or Relapsed Acute Leukemia Post Allogeneic BMT

Blood (2021) 138 (Supplement 1): 2828.

https://doi.org/10.1182/blood-2021-153207

Published: 2021

Journal Articles

Naïve Helper T-Cell and Regulatory T- and NK-Cell Subsets Are Associated with Pediatric Chronic Graft-Versus-Host Disease: Results of the ABLE / PBMTC 1202 Study

Blood (2020) 136 (Supplement 1): 11–12.

https://doi.org/10.1182/blood-2020-139031

Published: 2020

Journal Articles

Granulocyte Colony-Stimulating Factor Is Safe and Well Tolerated Following Allogeneic Transplantation in Patients with Sickle Cell Disease

Niketa C. Shah, MD, Sweta Bhoopatiraju, Allistair Abraham, MD, Eric Jon Anderson, MD, Martin Andreansky, MD, Monica Bhatia, MD, Sonali Chaudhury, MD, Geoff D.E. Cuvelier, MD, Kamar Godder, MD MPH, Michael Grimley, MD, Gregory Hale, MD, Naynesh Kamani, David Jacobsohn, MD, Alexander I. Ngwube, MD, Jodi L. Skiles, MD, Lolie C. Yu, MD, Shalini Shenoy, MD

Blood (2020) 136 (Supplement 1): 33.

https://doi.org/10.1182/blood-2020-142696

Published: 2020

Journal Articles

Abatacept Is Effective for Gvhd Prophylaxis after Unrelated Donor Stem Cell Transplantation (URD SCT) for Severe Sickle Cell Disease (SCD)

Alexander I. Ngwube, MD, Niketa C. Shah, MD, David Jacobsohn, MD, Edward Dela Ziga, MD, Shalini Shenoy, MD

Blood (2019) 134 (Supplement_1): 370.

https://doi.org/10.1182/blood-2019-126405

Published: 2019

Journal Articles

A Refined Clinical Risk Score at Onset of Treatment for Acute Gvhd That Predicts Response to Initial Therapy, Survival and Transplant-Related Mortality

Margaret L. MacMillan, MD, Marie Robin, MD PhD, Andrew C Harris, MD, Todd E. Defor, MS, Paul J. Martin, MD, Amin Alousi, MD, Vincent T Ho, MD, Javier Bolanos-Meade, MD, James L.M. Ferrara, MD, D.Sc., Richard J. Jones, MD, Mukta Arora, MD MS, Bruce R. Blazar, MD, Shernan G. Holtan, MD, David Jacobsohn, MD, Marcelo C. Pasquini, MD MS, Gerard Socie, MD PhD, Joseph H. Antin, MD, John E. Levine, MD, M.S., Daniel J. Weisdorf, MD

Blood (2014) 124 (21): 188.

https://doi.org/10.1182/blood.V124.21.188.188

Published: 2014

Journal Articles

Recommended Tools for Joint Chronic Graft-Versus-Host Disease: Results From the Chronic Gvhd Consortium

Yoshihiro Inamoto, MD, PhD, Xiaoyu Chai, MS, Brenda Kurland, PhD, Daniel J. Weisdorf, MD, Paul J. Martin, MD, David Jacobsohn, MD, Joseph Pidala, MD, MS, Jeanne Palmer, MD, Sally Arai, MD, Corey Cutler, MD, MPH, FRCPC, Madan Jagasia, MBBS, MS, Mary E.D. Flowers, MD, Mukta Arora, MD, Steven Z. Pavletic, MD, Georgia B. Vogelsang, MD, Stephanie J. Lee, MD, MPH, Paul A. Carpenter, MD

Blood (2012) 120 (21): 464.

https://doi.org/10.1182/blood.V120.21.464.464

Published: 2012

Journal Articles

Change in NIH Skin Score 0–3 Correlates with Provider- and Patient-Reported Skin Changes and Overall Survival: Results From the Chronic Gvhd Consortium

David Jacobsohn, MD, Stephanie J. Lee, MD, MPH, Brenda Kurland, PhD, Corey S. Cutler, MD, MPH, FRCPC, Joseph Pidala, MD, MS, Paul A. Carpenter, MD, Shawn Chai, Sally Arai, MD, Mukta Arora, MD, Jeanne Palmer, MD, Paul J. Martin, MD, Steven Z. Pavletic, MD, Mary E.D. Flowers, MD

Blood (2011) 118 (21): 151.

https://doi.org/10.1182/blood.V118.21.151.151

Published: 2011

Journal Articles

Calculated NIH Response Correlates with Changes in Patient-Reported Symptoms but Not with Quality of Life: Results From the Chronic Gvhd Consortium

Yoshihiro Inamoto, MD, Corey S. Cutler, MD, MPH, FRCPC, Xiaoyu Chai, MS, Mukta Arora, MD, Paul J. Martin, MD, Joseph Pidala, MD, MS, Jeanne Palmer, MD, Steven Z. Pavletic, MD, Madan H. Jagasia, MD, David Jacobsohn, MD, Paul A. Carpenter, MD, Mary E.D. Flowers, MD, Nandita Khera, MD, Georgia B. Vogelsang, MD, Daniel J. Weisdorf, MD, Barry Storer, PhD, Stephanie J. Lee, MD, MPH

Blood (2011) 118 (21): 1988.

https://doi.org/10.1182/blood.V118.21.1988.1988

Published: 2011

Journal Articles

Global and organ-specific chronic graft-versus-host disease severity according to the 2005 NIH Consensus Criteria

Sally Arai, Madan Jagasia, Barry Storer, Xiaoyu Chai, Joseph Pidala, Corey Cutler, Mukta Arora, Daniel J. Weisdorf, Mary E. D. Flowers, Paul J. Martin, Jeanne Palmer, David Jacobsohn, Steven Z. Pavletic, Georgia B. Vogelsang, Stephanie J. Lee

Blood (2011) 118 (15): 4242–4249.

https://doi.org/10.1182/blood-2011-03-344390

Published: 2011

Journal Articles

Patient-reported quality of life is associated with severity of chronic graft-versus-host disease as measured by NIH criteria: report on baseline data from the Chronic GVHD Consortium

Joseph Pidala, Brenda Kurland, Xiaoyu Chai, Navneet Majhail, Daniel J. Weisdorf, Steven Pavletic, Corey Cutler, David Jacobsohn, Jeanne Palmer, Sally Arai, Madan Jagasia, Stephanie J. Lee

Blood (2011) 117 (17): 4651–4657.

https://doi.org/10.1182/blood-2010-11-319509

Published: 2011

Includes: Supplemental data

Journal Articles

Chronic Gvhd Global Severity According to NIH Consensus Criteria: Results From the Chronic Gvhd Consortium

Sally Arai, MD, Madan Jagasia, MD, MS, Mukta Arora, MD, David Miklos, MD, PhD, Xiaoyu Chai, MS, Barry Storer, PhD, Paul J. Martin, Corey Cutler, MD, MPH, FRCPC, Daniel J. Weisdorf, MD, Joseph Pidala, Jeanne Palmer, MD, Mary Flowers, MD, David Jacobsohn, MD, Paul A. Carpenter, Steven Z. Pavletic, MD, Georgia B. Vogelsang, MD, Stephanie J. Lee

Blood (2010) 116 (21): 220.

https://doi.org/10.1182/blood.V116.21.220.220

Published: 2010

Journal Articles

Quality of Life and Chronic Gvhd Severity According to the NIH Criteria: Results From the Chronic Gvhd Consortium

Joseph Pidala, MD, MS, Brenda Kurland, PhD, Shawn Chai, Navneet S. Majhail, MD, MS, Daniel J. Weisdorf, MD, Corey Cutler, MD, MPH, FRCPC, Madan Jagasia, MD, MS, Jeanne Palmer, MD, Mukta Arora, MD, Paul J. Martin, David Jacobsohn, MD, Georgia B. Vogelsang, MD, Steven Z. Pavletic, MD, Stephanie J. Lee

Blood (2010) 116 (21): 393.

https://doi.org/10.1182/blood.V116.21.393.393

Published: 2010

Journal Articles

Pediatric Myelodysplastic Syndromes and Allogeneic Hematopoietic Progenitor Cell Transplantation (HPCT): A Single Center Perspective.

Jeffrey R. Andolina, MD, Morris Kletzel, MD, David Jacobsohn, MD, ScM, William T. Tse, MD, PhD, Jennifer Schneiderman, MD, MS, Reggie Duerst, MD, Irene Helenowski, Sonali Chaudhury, M.D.

Blood (2009) 114 (22): 1780.

https://doi.org/10.1182/blood.V114.22.1780.1780

Published: 2009

Journal Articles

Correlation of the NIH and Vienna Skin Scores with Provider and Patient-Reported Skin Changes in Chronic Graft-Versus-Host Disease (GVHD).

David Jacobsohn, MD, ScM, Xiaoyu Chai, MS, Brenda Kurland, PhD, Sally Arai, MD, Mukta Arora, MD, MS, Corey Cutler, MD, MPH, Madan Jagasia, MD, MS, Steven Z. Pavletic, MD, Georgia Vogelsang, Stephanie J. Lee, MD, MPH, Mary E.D. Flowers, MD

Blood (2009) 114 (22): 2256.

https://doi.org/10.1182/blood.V114.22.2256.2256

Published: 2009

Journal Articles

Long-Term Survival and Late Deaths in 2-Year Survivors of Myeloablative Allogeneic Hematopoietic-Cell Transplantation for Hematologic Disorders.

John R. Wingard, MD, Navneet S. Majhail, MD, MS, Ruta Bajorunaite, PhD, Zhiwei Wang, MS, Kathleen A. Sobocinski, MS, David Jacobsohn, MD, Mohamed L Sorror, J. Douglas Rizzo, MD, MS, Brian J. Bolwell, Gérard Socié, MD

Blood (2009) 114 (22): 520.

https://doi.org/10.1182/blood.V114.22.520.520

Published: 2009

Journal Articles

Age-Dependent Pharmacokinetic Profile of Single Daily Dose Intravenous Busulfan in Children Undergoing Reduced-Intensity Conditioning Stem Cell Transplantation

William T. Tse, MD, PhD, Reggie Duerst, MD, Jennifer Schneiderman, MD, MS, Sonali Chaudhury, M.D., David Jacobsohn, MD, Morris Kletzel, MD

Blood (2008) 112 (11): 796.

https://doi.org/10.1182/blood.V112.11.796.796

Published: 2008

Journal Articles

Potential Increase in Graft Failure Risk after Reduced Intensity Conditioning Stem Cell Transplant (RIT) Using Umbilical Cord Blood for Children with Primary Immunodeficiency.

Jessica Guarino, MSN, MPH, Morris Kletzel, M.D., Reggie Duerst, M.D., David Jacobsohn, M.D., M.S., Jennifer Schneiderman, M.D., M.S., William T. Tse, M.D., Ph.D.

Blood (2007) 110 (11): 2006.

https://doi.org/10.1182/blood.V110.11.2006.2006

Published: 2007

Journal Articles

Use of Mesenchymal Stem Cells To Treat Pediatric Patients with Severe (Grade III–IV) Acute Graft Versus Host Disease Refractory to Steroid and Other Agents on a Compassionate Use Basis.

Vinod K. Prasad, MD, MRCP, Kenneth G. Lucas, MD, Gary I. Kleiner, MD, PhD, July-An M. Talano, MD, David Jacobsohn, MD, Paul Szabolcs, MD, Rod Monroy, PhD, Joanne Kurtzberg, MD

Blood (2007) 110 (11): 2971.

https://doi.org/10.1182/blood.V110.11.2971.2971

Published: 2007

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Higher abatacept exposure after transplant decreases acute GVHD risk without increasing adverse events

Phase I Study to Improve Anti-Viral Immunity after Cord Blood Transplantation Using Cord-Blood-Derived Multi-Virus-Specific T-Cells

Outcome of Donor-Derived Tumor Associated Antigen-Specific T Cell Therapy in Patients with High-Risk or Relapsed Acute Leukemia Post Allogeneic BMT

Naïve Helper T-Cell and Regulatory T- and NK-Cell Subsets Are Associated with Pediatric Chronic Graft-Versus-Host Disease: Results of the ABLE / PBMTC 1202 Study

Granulocyte Colony-Stimulating Factor Is Safe and Well Tolerated Following Allogeneic Transplantation in Patients with Sickle Cell Disease

Abatacept Is Effective for Gvhd Prophylaxis after Unrelated Donor Stem Cell Transplantation (URD SCT) for Severe Sickle Cell Disease (SCD)

A Refined Clinical Risk Score at Onset of Treatment for Acute Gvhd That Predicts Response to Initial Therapy, Survival and Transplant-Related Mortality

Recommended Tools for Joint Chronic Graft-Versus-Host Disease: Results From the Chronic Gvhd Consortium

Change in NIH Skin Score 0–3 Correlates with Provider- and Patient-Reported Skin Changes and Overall Survival: Results From the Chronic Gvhd Consortium

Calculated NIH Response Correlates with Changes in Patient-Reported Symptoms but Not with Quality of Life: Results From the Chronic Gvhd Consortium

Global and organ-specific chronic graft-versus-host disease severity according to the 2005 NIH Consensus Criteria

Patient-reported quality of life is associated with severity of chronic graft-versus-host disease as measured by NIH criteria: report on baseline data from the Chronic GVHD Consortium

Chronic Gvhd Global Severity According to NIH Consensus Criteria: Results From the Chronic Gvhd Consortium

Quality of Life and Chronic Gvhd Severity According to the NIH Criteria: Results From the Chronic Gvhd Consortium

Pediatric Myelodysplastic Syndromes and Allogeneic Hematopoietic Progenitor Cell Transplantation (HPCT): A Single Center Perspective.

Correlation of the NIH and Vienna Skin Scores with Provider and Patient-Reported Skin Changes in Chronic Graft-Versus-Host Disease (GVHD).

Long-Term Survival and Late Deaths in 2-Year Survivors of Myeloablative Allogeneic Hematopoietic-Cell Transplantation for Hematologic Disorders.

Age-Dependent Pharmacokinetic Profile of Single Daily Dose Intravenous Busulfan in Children Undergoing Reduced-Intensity Conditioning Stem Cell Transplantation

Potential Increase in Graft Failure Risk after Reduced Intensity Conditioning Stem Cell Transplant (RIT) Using Umbilical Cord Blood for Children with Primary Immunodeficiency.

Use of Mesenchymal Stem Cells To Treat Pediatric Patients with Severe (Grade III–IV) Acute Graft Versus Host Disease Refractory to Steroid and Other Agents on a Compassionate Use Basis.

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only